Novasep’s European Custom Manufacturing Passes FDA Inspection
News Oct 24, 2013

Novasep has successfully audited two of its European custom manufacturing sites in Le Mans, France and Leverkusen, Germany.
FDA investigators audited the two facilities in June and July 2013.
The FDA audit at the Novasep site in Le Mans was a pre-approval inspection for production of paclitaxel, a long-established anticancer parenteral active ingredient for which Novasep is one of the world’s leading suppliers.
The positive outcome of the audit in Le Mans demonstrates the capability of the team to handle highly potent active pharmaceutical ingredients (HPAPI), in particular paclitaxel.
Novasep has held European CEP (Certificate of Suitability) for paclitaxel since 2011 and an FDA drug master file (DMF) since 1996.
The Leverkusen facility audit included both a pre-approval inspection of the production of formulated nitroglycerine and an overall cGMP (Good Manufacturing Practices) inspection on all products made for the US market.
“The FDA has tightened up its surveillance and audits,” said Michel Spagnol, CEO at Novasep. “Adhering to regulatory requirements is critical, although it is becoming progressively more challenging across the industry. Our teams’ commitment to quality is impressive. I am very pleased with our continued track record in securing FDA inspection approval and the added assurance these successes give our global customers.”
“The two successful FDA inspections demonstrate that Novasep’s custom synthesis facilities are operated under a robust quality management system,” said Jean-Claude Romain, VP of quality at Novasep.
Romain continued, “A quality assurance system does not remain static. It constantly evolves due to experience, multiple customer feedback and regulatory inspections. In addition, FDA inspections provide excellent opportunities for further improvement. The successes of the audits not only result from the quality systems Novasep has in place, but also from the day-to-day involvement of each person on the team.”
RELATED ARTICLES
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine Yields
NewsExtends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.
READ MOREPhoreMost and Plexxikon Collaborate to Identify Novel Drug Targets
NewsPhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.
READ MORELonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
NewsFirst-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
BiopharmaTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
Login
You must be logged in to post a comment.